Scientists can now design bacteria-killing viruses from DNA, opening a faster path to fighting superbugs.
Bacteriophages have been used as treatments for bacterial infections for more than a century. Interest in these viruses is rising again as antibiotic-resistant infections become an increasing threat to public health. Even so, progress in the field has been slow. Most research has relied on naturally occurring phages because traditional engineering methods are time consuming and difficult, limiting the development of customized therapeutic viruses.
A Fully Synthetic Phage Engineering Breakthrough
In a new PNAS study, scientists from New England Biolabs (NEB) and Yale University describe the first fully synthetic system for engineering bacteriophages that target Pseudomonas aeruginosa, an antibiotic-resistant bacterium that poses a serious global health concern. The work is powered by NEB's High-Complexity Golden Gate Assembly (HC-GGA) platform, which allows phages to be designed and built using DNA sequence information rather than physical virus samples.
Using this approach, the researchers constructed a P. aeruginosa phage from 28 synthetic DNA fragments. They then altered the virus by introducing point mutations along with DNA insertions and deletions. These changes allowed the team to modify which bacteria the phage could infect by swapping tail fiber genes and to add fluorescent reporters that made infections visible as they happened.
"Even in the best of cases, bacteriophage engineering has been extremely labor-intensive. Researchers spent entire careers developing processes to engineer specific model bacteriophages in host bacteria," reflects Andy Sikkema, the paper's co-first author and Research Scientist at NEB. "This synthetic method offers technological leaps in simplicity, safety, and speed, paving the way for biological discoveries and therapeutic development."
Building Phages From Digital DNA
NEB's Golden Gate Assembly platform makes it possible to assemble a complete phage genome outside the cell using synthetic DNA, with all planned genetic changes included from the start. Once assembled, the genome is introduced into a safe laboratory strain where it becomes an active bacteriophage.
This process removes many long-standing barriers in phage research. Scientists no longer need to maintain collections of fragile phage isolates or rely on specialized host bacteria, which is especially challenging for phages that infect dangerous human pathogens. The method also avoids the repeated screening and step-by-step genetic editing required by approaches that modify phages inside living cells.
Why Golden Gate Assembly Matters
Compared with DNA assembly techniques that use fewer but longer fragments, Golden Gate Assembly works with shorter DNA segments. These shorter pieces are easier to prepare, less harmful to host cells, and less likely to contain errors. The method is also more tolerant of repeated sequences and extreme GC content, features that are common in many phage genomes.
By simplifying the engineering process and expanding what can be built, the Golden Gate method greatly broadens the possibilities for scientists working to develop bacteriophages as tools to combat antibiotic resistance.
Collaboration Drives New Applications
The development of this rapid synthetic phage engineering approach required close collaboration between NEB scientists and bacteriophage researchers at Yale University. NEB researchers had already created the foundational tools needed to make Golden Gate Assembly reliable for large DNA targets made from many fragments. Yale researchers recognized the potential of these tools and initiated a partnership to explore more ambitious uses.
The method was first refined using a well-studied model virus, Escherichia coli phage T7. Since then, collaborative teams have expanded the approach to include non model bacteriophages that target highly antibiotic-resistant bacteria.
A related study using the Golden Gate method to build high GC content Mycobacterium phages was published in PNAS in November 2025 in collaboration with the Hatfull Lab at the University of Pittsburgh and Ansa Biotechnologies. In another project, researchers from Cornell University worked with NEB to develop synthetically engineered T7 bacteriophages that function as biosensors capable of detecting E. coli in drinking water, described in a December 2025 ACS study.
"My lab builds 'weird hammers' and then looks for the right nails," said Greg Lohman, Senior Principal Investigator at NEB and co-author on the study. "In this case, the phage therapy community told us, 'That's exactly the hammer we've been waiting for.'"
Reference: "A fully synthetic Golden Gate assembly system for engineering a Pseudomonas aeruginosa phiKMV-like phage" by Andrew P. Sikkema, Kaitlyn E. Kortright, Hemaa Selvakumar, Jyot Antani, Benjamin K. Chan, Matthew Davidson, Max Hopkins, Benjamin Newman, Vladimir Potapov, Cecilia A. Silva-Valenzuela, S. Kasra Tabatabaei, Robert McBride, Paul E. Turner and Gregory J. S. Lohman, 23 January 2026, Proceedings of the National Academy of Sciences.
DOI: 10.1073/pnas.2525963123
News
Unzipping the Code of Life: Scientists Pinpoint Where DNA First Opens
Researchers mapped where DNA first opens and how a helicase gate may release one strand as genome copying begins. Before a cell can divide, it must open its tightly wound DNA and begin copying the entire [...]
Scientists Tested an 8-Hour Eating Window and Found a Surprising Brain Benefit
Limiting the daily eating window may provide brain benefits beyond those associated with weight loss. Eating within a shorter daily window may provide cognitive benefits beyond those associated with weight loss alone, according to [...]
Focused Ultrasound Opens Blood-Brain Barrier to Treat Brain Cancer
Summary: A new study demonstrates that primary brain tumors (gliomas) are particularly receptive to targeted drug delivery using focused ultrasound (FUS) combined with microbubbles. The team developed a high-resolution MRI protocol to track blood-brain barrier [...]
AI’s promise and practical limits in drug discovery
AI tools are becoming increasingly common in early drug discovery, allowing scientists to analyse data and navigate large volumes of research. However, according to Dr Raminderpal Singh, turning that potential into consistent scientific workflows [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Healthcare Headlines: Challenges and Advances in 2026
Health-related updates reveal financial adjustments by Universal Health Services due to Medicaid reimbursement uncertainties, significant pollution-linked health concerns from French-British oil firm Perenco in Congo, drug trial setbacks, potential restructuring at major medical firms, [...]
Scientists Discover the Brain Protein That Helps Alzheimer’s Spread Through the Brain
Scientists have identified a brain protein that may help Alzheimer’s spread, revealing a potential new target for slowing the disease’s progression. Alzheimer’s disease is closely linked to the accumulation of a toxic form of the protein [...]
How Immune Dysregulation Contributes to Psychiatric Disorders
Introduction Growing evidence suggests that disruptions in immune function may play an important role in the development and progression of psychiatric disorders. However, immune mechanisms probably contribute more strongly in some patients than others, [...]
Electrostatic Discharge Boosts Triboelectric Nanogenerator Current and Enables DC Output
Controlled electrical discharges could enable triboelectric nanogenerators to achieve higher peak currents, extending nano-enabled energy harvesting into chemical processing and self-powered sensing. Paper: Electrostatic discharge as a breakthrough strategy for triboelectric nanogenerators. A new review [...]
Swiss laboratory uses old drugs against rare diseases
Researchers at the University of Geneva are combing through collections of approved drugs to find new therapies for rare diseases – with some success. This approach is gaining traction around the world, while pharmaceutical [...]
Nanozyme Aptasensors Show Promise for Faster Food, Health, and Environmental Testing
By pairing robust artificial enzymes with highly selective aptamers, nanozyme aptasensors could help detect disease biomarkers, pathogens, and contaminants faster, but the review shows that real-world deployment still depends on overcoming matrix interference, biofouling, [...]
Paralyzed Man Feels Sensation Again With Brain Stimulation Device
Aneuroprosthetic system has allowed a man with paralysis to grasp and lift objects and feel touch again. The device helped 42-year-old Keith Thomas of Massapequa, New York, who was paralyzed from the chest down [...]
Global Cancer Cases Could Surge 67% by 2050, New Report Warns
New data reveal major geographic disparities and highlight the urgent need for global action on prevention, early detection, and equitable access to treatment. For roughly one in five people worldwide, cancer will become part [...]
A Deadly Ebola-Like Virus Is Spreading. Are We Ready?
BU virologist Nancy Sullivan says the Bundibugyo outbreak in the Democratic Republic of the Congo underscores the need for broader outbreak preparedness. The death of a nurse marked the moment health officials recognized that [...]
Why Most Animal Viruses Never Become Human Pandemics
From receptor mismatch to risky human-animal interfaces, this article explains why spillover is common but true pandemic emergence remains rare. Introduction Humans are constantly exposed to animal viruses through farming, wildlife contact, and the [...]
Stem cell organoids repair heart microvessels in coronary artery disease models
A Stanford University team has shown that vascular organoids derived from human stem cells can repair the heart’s microvessel network in pigs with ischaemic heart disease – a proof-of-concept advancement that could open new therapeutic [...]















